Lightowler S, Wood M, Brown T, Glen A, Blackburn T, Tulloch I, Kennett G
SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK.
Eur J Pharmacol. 1996 Jan 25;296(2):137-43. doi: 10.1016/0014-2999(95)00704-0.
The effect of fluoxetine on feeding in p-chlorophenylalanine (PCPA) pretreated rats and the nature of its interaction with 5-HT2C receptors have been investigated. Animals that received 3 days PCPA (150 mg/kg i.p.) pretreatment and vehicle on the test day consumed a similar amount as control, saline pretreated animals under the test paradigm used in this study. Fluoxetine (20 and 30 mg/kg p.o.) significantly reduced food intake in PCPA and control pretreated animals to a similar extent, despite an approximately 90% reduction in the levels of brain 5-hydroxytryptamine (5-HT) and 5-hydroxyindole acetic acid (5-HIAA) in the PCPA-pretreated animals. Thus, hypophagia is unlikely to be caused by inhibition of 5-HT reuptake. In the pig choroid plexus in vitro, fluoxetine and norfluoxetine inhibited specific [3H] mesulergine binding with pKI's (+/- S.E.M.) of 6.45 +/- 0.09 (n = 4) and 6.05 +/- 0.05 (n = 3), and slope factors (+/- S.E.M.) of 1.06 +/- 0.14 and 0.99 +/- 0.13, respectively. In slices of piglet choroid plexus fluoxetine (1, 10 and 33 microM) caused a rightward shift in the dose-response curve produced by 5-HT with no effect on the maximal response, and a mean pKB of 5.94 +/- 0.09. Norfluoxetine (10 microM) also produced a rightward shift in the 5-HT dose-response curve with no effect on the maximal response, and a pKB of 6.20. Thus, both compounds acted as surmountable antagonists with no agonist efficacy at 5-HT2C receptors present in choroid plexus. The hypophagic effect of fluoxetine (20 mg/kg p.o.) was also unaffected by the non-specific 5-HT2C receptor antagonist metergoline (2 and 5 mg/kg i.p.). These findings suggest that the hypophagic effect of fluoxetine is not likely to be dependent upon intact brain 5-hydroxytryptaminergic presynaptic function, nor is it mediated by an agonist action at the 5-HT2C receptor, but by an additional, unknown mechanism.
已研究了氟西汀对经对氯苯丙氨酸(PCPA)预处理大鼠进食的影响及其与5-HT2C受体相互作用的性质。在本研究使用的测试范式下,接受3天PCPA(150mg/kg腹腔注射)预处理且在测试日给予赋形剂的动物与接受生理盐水预处理的对照动物食量相似。氟西汀(20和30mg/kg口服)在PCPA预处理动物和对照预处理动物中均显著降低食物摄入量,且降低程度相似,尽管PCPA预处理动物的脑5-羟色胺(5-HT)和5-羟吲哚乙酸(5-HIAA)水平降低了约90%。因此,食欲减退不太可能是由5-HT再摄取抑制引起的。在体外猪脉络丛中,氟西汀和去甲氟西汀抑制特异性[3H]美舒麦角结合,其pKI(±标准误)分别为6.45±0.09(n = 4)和6.05±0.05(n = 3),斜率因子(±标准误)分别为1.06±0.14和0.99±0.13。在仔猪脉络丛切片中,氟西汀(1、10和33μM)使5-HT产生的剂量反应曲线右移,对最大反应无影响,平均pKB为5.94±0.09。去甲氟西汀(10μM)也使5-HT剂量反应曲线右移,对最大反应无影响,pKB为6.20。因此,这两种化合物在脉络丛中存在的5-HT2C受体上均作为可克服的拮抗剂,无激动剂活性。氟西汀(20mg/kg口服)的食欲减退作用也不受非特异性5-HT2C受体拮抗剂美替拉酮(2和mg/kg腹腔注射)的影响。这些发现表明,氟西汀的食欲减退作用不太可能依赖于完整的脑5-羟色胺能突触前功能,也不是由5-HT2C受体的激动剂作用介导的,而是由一种额外的、未知的机制介导的。